CLINICAL_TRIALS
trial_result
· 2017-06-09
Clinical Trial Update: Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC [Phase 2]
Summary
Phase II trial of vinflunine in combination with cetuximab for second-line non-small cell lung cancer was terminated, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-06-09